hVIVO
2
23M
2
0.06
1
- Areas of investment
Summary
hVIVO appeared to be the Corporate Investor, which was created in 1988. The leading representative office of defined Corporate Investor is situated in the London. The company was established in Europe in United Kingdom.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2016.
The standard case for the fund is to invest in rounds with 2 partakers. The meaningful sponsors for the fund in investment in the same round are SEEK Group, Johnson & Johnson Innovation.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Among the most successful fund investment fields, there are Biotechnology, Health Care. Among the various public portfolio startups of the fund, we may underline Imutex
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 1
- Rounds per year
- 0.06
- Investments by industry
- Health Care (2)
- Biotechnology (2)
- Therapeutics (1)
- Medical (1)
- Health Diagnostics (1)
- Investments by region
-
- United Kingdom (2)
- Peak activity year
- 2015
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Imutex | 28 Apr 2016 | Biotechnology, Health Care, Health Diagnostics | Seed | 19M | United Kingdom, London, England |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.